Literature DB >> 18427761

[A 42 year old patient with bilateral loss of sight and hypertension. Gemcitabine-associated thrombotic microangiopathy (TMA)].

A Schmidt1, N Schwella, U Helmchen, D von Renteln, K Caca.   

Abstract

We report a case of a 42 year old male patient with a history of adrenocortical carcinoma, who was admitted with bilateral loss of sight and hypertension. Laboratory tests and further clinical evaluation showed hemolytic anemia, thrombocytopenia and acute renal failure. This was consistent with thrombotic microangiopathy / hemolytic uremic syndrome (HUS) due to gemcitabine therapy. The patient was successfully treated with prednisolon and antihypertensive drugs. Visus was completely restored, plasmapheresis was not needed. Clinicians should be aware of HUS as a rare complication of gemcitabine therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18427761     DOI: 10.1007/s00108-008-2123-y

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  22 in total

1.  Effectiveness of therapeutic plasma exchange in the 1996 Lanarkshire Escherichia coli O157:H7 outbreak.

Authors:  S Dundas; J Murphy; R L Soutar; G A Jones; S J Hutchinson; W T Todd
Journal:  Lancet       Date:  1999-10-16       Impact factor: 79.321

2.  [Renal failure, thrombocytopenia and hemolytic anemia in a 36-year-old patient].

Authors:  E Biecker; C Schwarze; Y D Ko; T Sauerbruch
Journal:  Internist (Berl)       Date:  2001-07       Impact factor: 0.743

Review 3.  HUS and TTP: variable expression of a single entity.

Authors:  G Remuzzi
Journal:  Kidney Int       Date:  1987-08       Impact factor: 10.612

4.  Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group.

Authors:  G A Rock; K H Shumak; N A Buskard; V S Blanchette; J G Kelton; R C Nair; R A Spasoff
Journal:  N Engl J Med       Date:  1991-08-08       Impact factor: 91.245

5.  Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases.

Authors:  A Veyradier; B Obert; A Houllier; D Meyer; J P Girma
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

Review 6.  How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.

Authors:  J N George
Journal:  Blood       Date:  2000-08-15       Impact factor: 22.113

7.  Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.

Authors:  H M Tsai; E C Lian
Journal:  N Engl J Med       Date:  1998-11-26       Impact factor: 91.245

8.  von Willebrand factor-cleaving protease (ADAMTS-13) activity determination in the diagnosis of thrombotic microangiopathies: the Swiss experience.

Authors:  Johanna A Kremer Hovinga; Jan-Dirk Studt; Lorenzo Alberio; Bernhard Lämmle
Journal:  Semin Hematol       Date:  2004-01       Impact factor: 3.851

9.  Endothelial microparticles released in thrombotic thrombocytopenic purpura express von Willebrand factor and markers of endothelial activation.

Authors:  Joaquin J Jimenez; Wenche Jy; Lucia M Mauro; Lawrence L Horstman; Carl Soderland; Yeon S Ahn
Journal:  Br J Haematol       Date:  2003-12       Impact factor: 6.998

10.  Mitomycin-induced hemolytic uremic kidney. An experimental model in the rat.

Authors:  V Cattell
Journal:  Am J Pathol       Date:  1985-10       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.